Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMTRIX-D
- Development stage
- Phase 2
- Lead developer
- TBF Génie Tissulaire
- Administration
- Topical
01
Overview
AMTRIX-D is a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft developed by TBF Genie Tissulaire. It is designed to function as an anti-adhesive barrier following the surgical release of tendon adhesions (tenolysis), particularly in the hand. By wrapping the surgically released tendon, the membrane aims to reduce the recurrence of adhesions and promote the recovery of hand functionality. As a biological graft, it provides a physical barrier and a scaffold that supports tissue healing while minimizing inflammatory responses that lead to scarring and adhesion formation.
- Brand names
- AMTRIX-D
- Other names
- AMTRIX-D-TBF Genie Tissulaire-tendon adhesion
Beyond the preview
Go deeper on AMTRIX-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMTRIX-D.